GustavCharlesMagrinatMD

Physician

Dr. Magrinat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Duke University HospitalFellowship, Hematology and Medical Oncology, 1990 - 1993
Duke University HospitalResidency, Internal Medicine, 1987 - 1990
University of North Carolina at Chapel Hill School of MedicineClass of 1987

CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013
Top MD Consumers Checkbook

PubMed

5 citations
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer Jr, Catherine A Azar
Breast Cancer Research and Treatment. 2023-06-01
23 citations
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch
Journal of Clinical Oncology. 2021-03-19
43 citations
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Hyman B. Muss, Mei Yin C. Polley, Donald A. Berry, Heshan Liu, C. Cirrincione
Journal of Clinical Oncology. 2019-07-24

Journal Articles

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society